Teva announces Phase III results for allergy spray; Ipsen gets FDA go-ahead for drug delivery syringe;

> Ipsen Biopharmaceuticals received FDA approval for its low-volume, full-dose, one-time-use syringe made to deliver Somatuline Depot (lanreotide). Release

> Teva ($TEVA) announced positive findings in its phase III clinical study on children suffering from year-round and seasonal allergic rhinitis using QNASL, its waterless aerosol intranasal corticosteroid spray. Release

> Maine-based DoseOne, maker of the DoseOne single-dose dry powder inhaler, is looking for a device or pharmaceutical partner to bring the drug delivery device to market. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.